3-benzoyl-1-(2-bromoethyl)pyrimidine-2,4(1H,3H)-dione | 367493-18-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-benzoyl-1-(2-bromoethyl)pyrimidine-2,4(1H,3H)-dione
• 英文别名: 3-benzoyl-1-(2-bromoethyl)pyrimidine-2,4-dione
• CAS: 367493-18-3
• 化学式: C₁₃H₁₁BrN₂O₃
• 分子量: 323.146
• InChiKey: JPEXGODOTDWFKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  57.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-benzoyl-1-(2-bromoethyl)pyrimidine-2,4(1H,3H)-dione 在 ammonium hydroxide 、 四丁基氟化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 苯酚 为溶剂， 反应 6.0h， 生成 1-(2-(2-((1H-indol-4-yl)oxy)-5-chlorophenoxy)ethyl)pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group

  摘要：

  Members of the catechol diether class are highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). The most active compounds yield EC50 values below 0.5 nM in assays using human T-cells infected by wild-type HIV-1. However, these compounds such as rilpivirine, the most recently FDA-approved NNRTI, bear a cyanovinylphenyl (CVP) group. This is an uncommon substructure in drugs that gives reactivity concerns. In the present work, computer simulations were used to design bicyclic replacements for the CVP group. The predicted viability of a 2-cyanoindolizinyl alternative was confirmed experimentally and provided compounds with 0.4 nM activity against the wild-type virus. The compounds also performed well with EC50 values of 10 nM against the challenging HIV-1 variant that contains the Lys103Asn/Tyr181Cys double mutation in the RT enzyme. Indolyl and benzofuranyl analogues were also investigated; the most potent compounds in these cases have EC50 values toward wild-type HIV-1 near 10 nM and high-nanomolar activities toward the double-variant. The structural expectations from the modeling were much enhanced by obtaining an X-ray crystal structure at 2.88 Å resolution for the complex of the parent 2-cyanoindolizine 10b and HIV-1 RT. The aqueous solubilities of the most potent indolizine analogues were also measured to be ~40 μg/mL, which is similar to that for the approved drug efavirenz and ~1000-fold greater than for rilpivirine.

  DOI：

  10.1021/ja408917n
• 作为产物：
  描述：

  苯甲酰氯 在 potassium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 2.0h， 生成 3-benzoyl-1-(2-bromoethyl)pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  使用氟硫酸盐弹头共价抑制野生型 HIV-1 逆转录酶

  摘要：

  据报道，野生型 HIV-1 逆转录酶 (CRTI) 的共价抑制剂。三种源自儿茶酚二醚非核苷抑制剂 (NNRTI) 并添加氟硫酸弹头的化合物被证明可以共价修饰 HIV-RT 的 Tyr181。提供了 CRTI 与酶复合物的 X 射线晶体结构，充分证明了共价连接，并通过 ESI-TOF 质谱中适当的质量位移进行了确认。三种 CRTI 和六种非共价类似物被发现是有效的抑制剂，其体外抑制 WT RT 的 IC 50值和对 HIV-1 感染的人类 T 细胞进行细胞病变保护的 EC 50值均在 5-320 nM 范围内。

  DOI：

  10.1021/acsmedchemlett.0c00612

文献信息

• Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents
  作者：Won-Gil Lee、Albert H. Chan、Krasimir A. Spasov、Karen S. Anderson、William L. Jorgensen

  DOI：10.1021/acsmedchemlett.6b00390

  日期：2016.12.8

  7-cyano-2-naphthyl substituent are reported as non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). Many of the compounds have 1–10 nM potencies toward wild-type HIV-1. An interesting conformational effect allows two unique conformers for the naphthyl group in complexes with HIV-RT. X-ray crystal structures for 4a and 4f illustrate the alternatives.

  据报道，掺有7-氰基-2-萘基取代基的邻苯二酚二醚是HIV-1逆转录酶（NNRTIs）的非核苷抑制剂。许多化合物对野生型HIV-1的效价为1-10 nM。一个有趣的构象效应使得与HIV-RT形成复合物的萘基具有两个独特的构象体。4a和4f的X射线晶体结构说明了替代方案。
• Synthesis by conjugate radical addition of new heterocyclic amino acids with nucleobase side chains
  作者：Raymond C.F Jones、Didier J.C Berthelot、James N Iley

  DOI：10.1016/s0040-4020(01)00546-4

  日期：2001.7

  N-(2-iodoethyl) and N-(3-iodopropyl)pyrimidines and purines undergo stereoselective conjugate radical addition with an optically active oxazolidinone acceptor to give syn-adducts that can be converted into amino acids carrying pyrimidine and purine (nucleobase) side chains.

  N-（2-碘乙基）和N-（3-碘丙基）嘧啶和嘌呤与光学活性的恶唑烷酮受体进行立体选择共轭基团加成，生成顺式加合物，可将其转化为带有嘧啶和嘌呤（核碱基）侧链的氨基酸。
• Synthesis by conjugate radical addition of new heterocyclic amino acids with nucleic acid bases in their side chains
  作者：Raymond C. F. Jones、Didier J. C. Berthelot、James N. Iley

  DOI：10.1039/b006843h

  日期：——

  N-(2-Iodoethyl) and N-(3-iodopropyl)pyrimidines and purines undergo stereoselective conjugate radical addition with an optically active oxazolidinone acceptor to give syn-adducts that can be converted into pyrimidine and purine amino acids.

  N-(2-碘乙基) 和 N-(3-碘丙基) 嘧啶和嘌呤与光学活性恶唑烷酮受体发生立体选择性共轭自由基加成反应，得到可转化为嘧啶和嘌呤氨基酸的顺式加合物。
• COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS
  申请人：YALE UNIVERSITY

  公开号：US20150105351A1

  公开（公告）日：2015-04-16

  The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.

  本发明涉及新型纳摩尔和皮摩尔HIV逆转录酶抑制剂，以及由此制备的药物组合物和用于抑制逆转录酶和治疗HIV感染的方法，特别包括对HIV-1和HIV-2的耐药菌株以及作为HIV感染后果发生的次生疾病状态和/或条件。
• Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography
  作者：Albert H. Chan、Won-Gil Lee、Krasimir A. Spasov、José A. Cisneros、Shalley N. Kudalkar、Zaritza O. Petrova、Amanda B. Buckingham、Karen S. Anderson、William L. Jorgensen

  DOI：10.1073/pnas.1711463114

  日期：2017.9.5

  HIV-1 reverse transcriptase (RT) has been the prime target for anti-HIV chemotherapy; however, its rapid mutation often generates drug resistance. Prominent variant strains of HIV-1 that lead to treatment failure with nonnucleoside RT inhibitors (NNRTIs) bear the Tyr181Cys mutation in RT. Based on our previous discovery and crystallography for potent noncovalent NNRTIs, new compounds were designed with incorporation of chemical warheads intended to modify covalently Cys181. Here we report on the success of the strategy, including biochemical, biophysical, and cellular evidence of the desired irreversible covalent inhibition. The new compounds completely eliminate the activity of Cys181-bearing RT, and it may be possible to dose them less frequently than noncovalent inhibitors.

  HIV-1反转录酶（RT）是抗HIV化疗的主要目标；然而，它的快速突变经常会产生药物抗性。导致非核苷类RT抑制剂（NNRTIs）治疗失败的突变HIV-1变异株携带RT中的Tyr181Cys突变。基于我们先前发现的有效非共价NNRTIs和晶体学，新化合物被设计成引入化学战争头，旨在共价修饰Cys181。在这里，我们报告了该策略的成功，包括所需的不可逆共价抑制的生物化学，生物物理和细胞证据。新化合物完全消除了携带Cys181的RT的活性，并且可能比非共价抑制剂更少地使用剂量。